Cytochrome P450 (CYP) enzymes are responsible for the metabolism of numerous xenobiotics and endogenous compounds, including the metabolic activation of most environmental toxic chemicals and carcinogens. Both metabolic and genetic polymorphisms have been identified for human CYP enzymes. The association of CYP genetic polymorphism and human cancer risk, and susceptibility to environmental hazards, have received increasing attention. This article briefly reviews the approaches and methods currently used in CYP genetic polymorphism studies. In addition, the current status and perspectives of using CYP genetic polymorphism as a biomarker of individual susceptibility to cancer and environmental toxicity are discussed. Environ Health involved in metabolizing a large number of environmental carcinogens and toxic compounds (1). Because an individual's capability to metabolize these toxicants can be altered by carrying the variant alleles, genetic polymorphisms of CYP enzymes have been proposed as a biomarker of susceptibility to environmental carcinogenesis and toxicity. This paper briefly reviews the methodologies for CYP polymorphism studies and emphasizes the comparison between the genotyping and phenotyping approaches. The use of genetic polymorphisms of human CYP enzymes as a susceptibility biomarker and the direction of future research will be discussed.
Cytochrome P450s (CYPs) are a superfamily of hemoproteins that catalyze the biotransformation of various xenobiotics and endobiotics (1, 2) . Although there are overlapping substrate specificities, individual CYP forms have significant differences in their substrate preferences. On the basis of this specificity, selective activity assays with different substrates have been used to establish markers for particular CYP forms.
It is well established that most environmental toxic chemicals and carcinogens need to be metabolically activated to exert their toxic or carcinogenic effects. As a major enzyme system in xenobiotic metabolism, CYPs (CYPlAI, 1A2,  2A6, 2C9, 2C19, 2D6, 2E1, and 3A4) have been shown to be polymorphic at the phenotypic or genotypic level, or both (3) (4) (5) . In addition to metabolizing various drugs, these polymorphic CYP enzymes are involved in metabolizing a large number of environmental carcinogens and toxic compounds (1) . Because an individual's capability to metabolize these toxicants can be altered by carrying the variant alleles, genetic polymorphisms of CYP enzymes have been proposed as a biomarker of susceptibility to environmental carcinogenesis and toxicity. This paper briefly reviews the methodologies for CYP polymorphism studies and emphasizes the comparison between the genotyping and phenotyping approaches. The use of genetic polymorphisms of human CYP enzymes as a susceptibility biomarker and the direction of future research will be discussed.
Phenotypic Determination of CYP Polymorphisms
It is well known that there are large interindividual variations in CYP-catalyzed drug biotransformation (1) . The CYP polymorphisms were initially identified by determining the metabolic ratio, i.e., the ratio of the blood or urinary amount of the parent drug over its metabolite, in individuals to whom the probe drug was administered.
Metabolic polymorphism is usually indicated in a population where the frequency distribution of the metabolic ratio is shown to be bimodal or trimodal. The bimodal distribution is due to the existence of poor and extensive metabolizers, whereas the trimodal distribution is caused by the presence of additional intermediate metabolizers. Examples for bimodal distribution include debrisoquine 4-hydroxylation (catalyzed by CYP2D6) and coumarin 7-hydroxylation (catalyzed by CYP2A6) (6) . The 3-demethylation of caffeine is an activity marker of CYP1A2, and a trimodal distribution for caffeine metabolism was observed in nonsmokers (7) .
Besides the metabolism in vivo, the polymorphisms of CYP enzymes can be determined at other phenotypic levels. These well documented in animals (9) . In humans, induction of CYP2E1 by alcohol drinking (10) and of CYP1A2 by ingestion of charbroiled meats or cruciferous vegetables have been observed (11) . In addition, human CYP1A2 is induced by cigarette smoking (12, 13) . Finally, the availability of substantial amounts of quality-assured human tissues (except peripheral blood cells) could be a limiting factor for determination of CYP enzyme activity in vitro, as well as for determination of CYP protein and mRNA levels.
Genetic Basis of Metabolic Polymorphisms
The genetic basis of several CYP-involved metabolic polymorphisms has been elucidated. Mutations (14) . After cDNA cloning and DNA sequencing, they demonstrated that a mutant 2D6allele is responsible for the majority of "poor metabolizers." Further work established that a mutation at a splicing site caused the production of dtfective 2D6 mRNA and a total absence of 2D6 protein (15) . Prior to labor-intensive DNA sequencing work, the possible DNA sequence alterations can now be screened by single-strand conformation polymorphism analysis that detects the mutation-caused mobility shift of the DNA fragments on gel electrophoresis (16) or by other methods such as denaturing gradient gel electrophoresis (17) . For functional analysis, the catalytic activity of CYP enzymes can be studied by expressing different variant CYP proteins with various cDNA expression systems if the polymorphic changes are localized in the coding region. If the polymorphic loci are in the noncoding region, their effects on the transcriptional regulation can be studied by linking the mutated sequence with a reporter gene.
Genotyping Approach
As long as the polymorphic sites of a CYP gene are clearly identified, it is simple to determine an individual's genotype by current molecular biology techniques. If a polymorphic site in a CYP gene changes the recognition sequence of a restriction enzyme, or if the genetic polymorphism involves a large deletion, the genetic polymorphism can be identified by restriction fragment length polymorphism (RFLP) analysis, in which DNA is subjected to Southern blotting after digestion with appropriate restriction enzymes and hybridized with specific probes.
Recent advances in PCR technology have greatly increased our capability to detect genetic polymorphisms of CYP enzymes. With small amounts of human tissue or cell samples, DNA amplification can be carried out with proper PCR primers for any particular sequence of a polymorphic CYP gene. The DNA source can be from blood leukocytes, buccal epithelial cells, hair roots, or normally exfoliated cells, such as bladder epithelium in the urine. DNA can also be obtained from stored pathological tissue sections, which provide great advantage for retrospective studies. It is now feasible to determine several CYP genetic polymorphisms with less than 10 pl of blood collected from the finger tip. The PCR-amplified DNA sequence containing the polymorphic sites can then be analyzed by RFLP with restriction digestion and visualized on a stained gel after electrophoresis. Comparing the wild-type samples, if the genetic polymorphism results in a loss-or in some cases a gainof a restriction site, the band pattern on the gel will be different. If the PCR primers are designed to be within the missing sequence of a deletion polymorphism, there will be no PCR product formed.
Obviously, the RFLP method cannot be used to screen the CYP genetic polymorphisms in which the DNA sequence alterations cause no changes at suitable restriction sites. In this case, genotyping can be carried out by allele-specific PCR with a set of mutation-specific primers for amplification. Several polymorphisms of CYPlA], 2A6, and 2D6have been identified by the allele-specific PCR method (18) (19) (20) . If necessary, the results from PCR-RFLP and allele-specific PCR can be confirmed by PCR-direct sequencing.
In contrast to the phenotyping approach, genotyping is not affected by drugs or dietary factors that might modulate the metabolic activity of CYP enzymes. As mentioned previously, the PCR-based genotyping techniques require only a small amount of DNA, which can be obtained by less invasive or noninvasive means or from longtime stored pathological samples. The genotyping approach also allows accurate prediction of the homozygous or heterozygous status of an individual who carries the variant allele. All of these are particularly useful for large population studies in which genetic polymorphisms of CYP enzymes may be susceptibility markers.
CYP Genetic Polymorphisms and Cancer Risk
The association of CYP genetic polymorphisms and human cancer risk has received increasing attention. Examples include CYPIA] with lung and breast cancers (21-23), CYP2D6with different types of cancer (24) , and CYP2EI with lung, liver, and nasopharyngeal cancers (21, (25) (26) (27) (28) . However, many reports are controversial. One important factor in interpreting these results is that there are significant ethnic differences in frequency distribution of the CYP genetic polymorphisms. For example, an association of CYP2E1 DraI genetic polymorphism and susceptibility to lung cancer was suggested in a study of a Japanese population (29) but was not observed in Caucasians (26, 27, 30) . This discrepancy was believed to be caused by a significantly low distribution frequency of CYP2E1 DraI polymorphism in Caucasian populations (27) .
Current Problems and Perspectives
Research on genetic polymorphisms of CYP enzymes can provide a molecular basis for interindividual variations in metabolizing drugs and envirormental toxic chemicals. In addition to this mechanistic information, the studies hold great promise in identifying susceptible individuals and protecting them from environmental toxicity. If (32) . Multiple polymorphic CYP enzymes are involved in metabolizing these carcinogens. Even for a given subpopulation mainly exposed to a single toxic chemical, it is possible that more than one form of CYP enzyme is involved in the activation or detoxification. Therefore, it is recommended that whenever possible a combinational polymorphism analysis on all the involved CYP forms be carried out to obtain a complete picture of the role of CYP enzymes in susceptibility to cancer and toxicity. The availability of current PCR technology allows us to use DNA samples stored for extensive periods (e.g., blood dotted on filter paper or pathological tissue sections) for the analysis of different CYP genetic polymorphisms. In addition, these DNA samples can be used for combinational genetic polymorphism analysis with the phase II metabolizing enzymes such as glutathione S-transferase and N-acetyltransferase, or DNA repair enzymes.
